康华生物(300841) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥137,942,758.51, a decrease of 55.70% compared to ¥311,367,042.84 in the same period last year[7]. - Net profit attributable to shareholders was ¥20,708,594.70, down 86.15% from ¥149,466,993.99 year-on-year[7]. - Basic and diluted earnings per share were both ¥0.1594, representing an 85.77% decrease from ¥1.1204 in the same period last year[7]. - Total operating revenue for the current period is ¥137,942,758.51, a decrease of 55.7% compared to ¥311,367,042.84 in the previous period[27]. - Net profit for the current period is ¥20,708,594.70, compared to ¥149,466,993.99 in the previous period, reflecting a significant decline[28]. - Total comprehensive income attributable to the parent company was CNY 20,708,594.70, compared to CNY 149,466,993.99 in the previous period, indicating a significant decrease[29]. Cash Flow and Assets - The net cash flow from operating activities was -¥16,686,433.97, a decline of 116.93% compared to ¥98,589,924.72 in the previous year[14]. - Current assets total ¥2,354,274,529.10, down from ¥2,488,001,102.09 at the beginning of the period, indicating a decrease of 5.4%[24]. - Cash and cash equivalents decreased to ¥931,949,521.90 from ¥1,001,326,623.71, a decline of 6.9%[23]. - The ending balance of cash and cash equivalents was CNY 681,949,521.90, down from CNY 1,007,828,965.84 in the previous period[32]. - The company reported a financial expense of -¥459,538.23, an improvement compared to -¥2,204,660.06 in the previous period[28]. Liabilities and Shareholder Information - Total liabilities amount to ¥415,450,340.07, a reduction from ¥580,073,577.69 in the previous period, representing a decrease of 28.5%[25]. - Total number of common shareholders at the end of the reporting period is 21,584[17]. - The largest shareholder, Aokang Group Co., Ltd., holds 12.26% of shares, totaling 16,305,468 shares, with 10,730,000 shares pledged[17]. - Wang Zhentao, a significant shareholder, owns 10.53% of shares, amounting to 14,004,687 shares, with 13,487,500 shares pledged[17]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 29.87% of total shares[17]. Operating Costs and Revenue Decline - The company reported a 32.75% decline in revenue after excluding the previous year's one-time overseas authorization income of ¥106,240,500.00[7]. - The company's operating costs decreased by 36.97% to ¥7,686,111.19 due to reduced vaccine sales[12]. - Total operating costs for the current period are ¥112,232,733.05, down 16.8% from ¥134,855,630.79 in the previous period[27]. Changes in Assets - Total assets at the end of the reporting period were ¥3,883,667,631.05, down 3.57% from ¥4,027,582,273.97 at the end of the previous year[7]. - Non-current assets total ¥1,529,393,101.95, slightly down from ¥1,539,581,171.88 at the beginning of the period[24]. - Accounts receivable decreased to ¥1,211,775,915.46 from ¥1,298,879,167.25, a reduction of 6.7%[23]. - Inventory increased to ¥188,083,939.24 from ¥176,882,114.20, an increase of 6.7%[23]. Share Repurchase and Restricted Shares - The company has a total of 3,000,000 shares repurchased, representing 2.26% of total share capital, not included in the top 10 shareholders[18]. - The total number of restricted shares at the beginning of the period was 12,454,048, with 1,401,515 shares released during the period[21]. - The company has a total of 11,052,533 restricted shares remaining at the end of the reporting period[21]. - Wang Zhentao's restricted shares remain unchanged at 10,503,515 due to lock-up agreements[20]. Investment Activities - Cash inflow from investment activities was CNY 260,116,367.66, compared to CNY 50,000,000.00 in the previous period, showing a substantial increase[32]. - Cash outflow from investment activities totaled CNY 331,760,357.62, up from CNY 135,789,842.57 in the previous period[32]. Other Observations - The company experienced a 79.68% decline in fair value gains to ¥106,031.53, attributed to changes in the fair value of its equity investments[12]. - Other current assets increased by 4427.75% to ¥9,089,810.09, primarily due to withholding of corporate income tax from overseas authorization[15]. - The company reported a 68.23% decrease in payable employee compensation to ¥10,600,668.63, reflecting the distribution of 2024 annual salaries[15]. - The company did not report any net profit from merged entities during the current or previous periods[29]. - There are no new strategies or significant market expansions mentioned in the provided documents[22].